Prudential Financial Inc. boosted its stake in Emergent Biosolutions, Inc. (NYSE:EBS) by 3.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,378 shares of the biopharmaceutical company’s stock after buying an additional 2,618 shares during the period. Prudential Financial Inc. owned 0.18% of Emergent Biosolutions worth $3,049,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp lifted its holdings in Emergent Biosolutions by 47.2% in the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after acquiring an additional 290,863 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Emergent Biosolutions by 7.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after purchasing an additional 152,029 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Emergent Biosolutions by 26.1% in the second quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock worth $22,707,000 after purchasing an additional 138,611 shares in the last quarter. Peregrine Capital Management LLC lifted its position in shares of Emergent Biosolutions by 40.8% in the third quarter. Peregrine Capital Management LLC now owns 454,857 shares of the biopharmaceutical company’s stock worth $18,399,000 after purchasing an additional 131,692 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK lifted its position in shares of Emergent Biosolutions by 7.3% in the second quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after purchasing an additional 118,894 shares in the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at $44.12 on Tuesday. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $1,802.77, a price-to-earnings ratio of 23.04, a PEG ratio of 1.20 and a beta of 1.24. Emergent Biosolutions, Inc. has a 12 month low of $27.94 and a 12 month high of $44.97.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. The firm had revenue of $149.43 million during the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the company earned $0.56 earnings per share. sell-side analysts predict that Emergent Biosolutions, Inc. will post 1.64 EPS for the current year.
In related news, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Wednesday, September 27th. The stock was sold at an average price of $39.50, for a total transaction of $311,457.50. Following the transaction, the executive vice president now directly owns 33,931 shares of the company’s stock, valued at approximately $1,340,274.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16. Following the sale, the chief executive officer now owns 215,642 shares of the company’s stock, valued at $9,223,008.34. The disclosure for this sale can be found here. Insiders have sold a total of 262,308 shares of company stock valued at $10,676,924 over the last 90 days. Corporate insiders own 16.50% of the company’s stock.
EBS has been the topic of a number of research reports. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Wednesday, October 25th. Wells Fargo & Company restated an “outperform” rating and issued a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Finally, BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $46.00.
ILLEGAL ACTIVITY NOTICE: “Prudential Financial Inc. Buys 2,618 Shares of Emergent Biosolutions, Inc. (EBS)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/12/emergent-biosolutions-inc-ebs-shares-bought-by-prudential-financial-inc.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.